The Imperative for Comparative Studies in Nuclear Medicine: Elevating 177 Lu-PSMA-617 in the Treatment Paradigm for mCRPC
Journal of Nuclear Medicine · 2024
DOI: 10.2967/jnumed.123.266952 ↗Kurz gefasst
Editorial in der Zeitschrift Journal of Nuclear Medicine, 2024. Verfasst von Kambiz Rahbar und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, University Hospital Muenster, Muenster, Germany; rahbar@unimuenster.de. Hauptthemen laut MEDLINE: Nuclear Medicine, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 9 Literaturangaben.
Abstract (Originalsprache)
Nuclear medicine, with its ever-evolving spectrum of diagnostic and therapeutic interventions, plays a pivotal role in the multidisciplinary approach to cancer care. In recent years, the emergence of targeted radioligands, such as 177Lu-PSMA-617, has offered renewed hope for patients with metastatic
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, University Hospital Muenster, Muenster, Germany; rahbar@unimuenster.de.
- West German Cancer Centre, Muenster, Germany; and.
- Department of Urology, University Hospital Muenster, Muenster, Germany.
Zitieren
APA
Rahbar, K., & Boegemann, M. (2024). The Imperative for Comparative Studies in Nuclear Medicine: Elevating 177 Lu-PSMA-617 in the Treatment Paradigm for mCRPC. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.123.266952
Vancouver
Rahbar K, Boegemann M. The Imperative for Comparative Studies in Nuclear Medicine: Elevating 177 Lu-PSMA-617 in the Treatment Paradigm for mCRPC. Journal of Nuclear Medicine. 2024. doi:10.2967/jnumed.123.266952
BibTeX
@article{Rahbar2024,
author = {Rahbar, Kambiz and Boegemann, Martin},
title = {The Imperative for Comparative Studies in Nuclear Medicine: Elevating 177 Lu-PSMA-617 in the Treatment Paradigm for mCRPC},
journal = {Journal of Nuclear Medicine},
year = {2024},
doi = {10.2967/jnumed.123.266952}
}
EUVIMED